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ABSTRACT
Background. Acute myeloid leukemia (AML) is characterized by clonal
expansion of undifferentiated myeloid precursors, resulting in impaired
hematopoiesis and bone marrow failure. Identification of new prognostic
markers remains important; especially those refining therapeutic options. The
aim of this study was to evaluate the value of Tetraspanin CD81 as a
prognostic marker in patients with de novo AML.
Methods. Thirty patients with newly diagnosed AML were included in this
study, and were subjected to immunophenotyping by flow cytometry. The
patients were followed up for one year to evaluate overall survival (OS) and
disease-free survival (DFS).
Results. CD81 was expressed in the thirteen patients with a mean percentage
31.15 ± 12.14 %. However, 17 AML patients were CD81- expression with
mean percentage 9.06 ± 3.78 %. After induction therapy, complete remission
achieved in 15 patients (50%). On the other hand, 13 patients (43.3%) did not
achieve complete remission, and the remaining 2 patients were not evaluated.
OS in AML patients ranged from (8- 12 months) with median 11.57 was
71.4%. DFS in AML patients with median 11 months was 53.6%. There was a
highly statistically significant difference between studied groups, where OS
and DFS were lower in patients with CD81+ expression compared tothose with
CD81- expression (P= 0.00).
Conclusion. CD81+ expression has a potential role as a prognostic marker;
where its expression is associated with M4 and M5 FAB subtypes. Moreover,
patients with CD81+ expression have higher incidence of relapse and
decreased OS & DFS than patients with CD81- expression.
Key words: Tetraspanin CD81, AML, Overall survival, Disease free survival.

INTRODUCTION
cute myeloid leukemia (AML) is
characterized by clonal expansion of
undifferentiated myeloid precursors, resulting
in impaired hematopoiesis and bone marrow
failure. The affected cells undergo an
uncontrolled proliferation and impaired
differentiation due to block at various
maturation steps [1]. Over the past few years,
identification of new prognostic markers
remains important; especially those refining
therapeutic options [2].
CD81 is a cell surface protein which
belongs to the Tetraspanin family, which is a
cell surface transmembrane protein. A murine
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monoclonal antibody was identified by its
ability to induce a reversible antiproliferative
effect on a human lymphoma cell line. Many
of the lymphoid cell lines, in particular those
derived from large cell lymphomas, were
susceptible to the antiproliferative effects of
the antibody. TAPA-1 may therefore play an
important role in the regulation of lymphoma
cell growth [3].
It regulates activation of B and T cells,
and immune receptor signaling [4]. Also, it
was reported to be involved as a gateway
molecule
in
hepatocytes
for
HCV
infectionand may have a similar role in
Plasmodium infection of red blood cells in
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malaria [5, 6].
CD81 allows hematopoietic stem cells to
re-enter to quiescence [7]. In hematologic
malignancies, CD81 has mostly been studied
in multiple myeloma where its expression on
plasma cells is associated with worse
progression free survival (PFS) and overall
survival (OS) [8]. Lastly, CD81 may be a new
prognostic marker for diagnostic risk
classification in AML [9].
Aim
The aim of this study is to evaluate the
value of Tetraspanin CD81 as a diagnostic
and prognostic marker in patients with de
novo AML.
PATIENTS AND METHODS
This study was carried out in Clinical
Pathology
and
Internal
medicine
Departmentsat our university hospitals, during
the period from February 2018 to February
2019. A total of 30 patients with newly
diagnosed AML were included in this study
after obtaining informed consent from all
individual participants. The responsible ethics
committees (Clinical Pathology Department
committee & Institutional Review Board
(IRB), Faculty of Medicine, Zagazig
University) have also given their approval.
This study was also conducted in compliance
with Declaration of Helsinki.
Participants enrolled in the study were
subjected to the following: full history taking;
clinical examination; complete blood count;
bone marrow aspiration and examination;
immunophenotyping by flow cytometry
(FCM) using Becton Dickenson FACSCalibur
device to detect the following markers: MPO,
CD13, CD33,HLADR, TDT, CD14, CD64,
CD34, CD3, CD19, CD20,CD22 and CD81;
conventional cytogenetic analysis and
karyotyping.
Specific laboratory investigations were
done with detection of CD81 (tetraspanin) on
blast cells by FCM. The percentage of blast
cells positive for the relevant studied marker
was determined as a percentage from the
gated blast cells population. Cut-off of MoAb
percent was defined for CD81 by running
samples for 10 apparently normal healthy
individuals (control group) - according to the
following formula; cut-off = mean + 2SD.
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The mean of CD81 positivity was 9.5 and the
SD was 4.6. Accordingly, the cut-off was
18.7, with CD81 <20 was considered
negative, and CD81 >20 was considered
positive.
There were 24 males and 6 females. Their
ages ranged from 17 to 75 years, with a mean
value of 40.9 ± 15.44 years. They were
followed up for one year. Peripheral blood
and bone marrow samples were collected
from all patients; at the time of presentation
and before initiation of therapy.
Patients were treated by an induction
regimen 3+7 regimen consisting of
continuous infusion cytarabine (100 mg/m²)
daily for 7 consecutive days combined with 3
days of doxorubicin (30 mg/m²). Patients with
60 years or poor performance status were
treated by 2+14 protocol consisting of 2 days
of doxorubicin (25 mg/m2) combined with 14
days of subcutaneous cytarabine (10
mg/m2/12 hours). Bone marrow aspiration
was performed on day 28 after receiving
induction
chemotherapy
to
evaluate
morphological remission.
Patients were followed once every 3
months with clinical examination and
complete blood cell counts. Bone marrow
examination was done if there was any doubt
of a relapse on clinical examination or blood
smear. The patients were followed up for one
year to evaluate OS and DFS.
Statistical analysis
Analysis of data was performed using
SPSS computer program (version 20; SPSS
Inc. Chicago, Illinois, USA). χ2 -test, t-test,
and Mann–Whitney test were used for
statistical analysis. DFS and OS were
estimated by the Kaplan–Meier method and
compared using the log-rank test. P value less
than 0.05 was considered statistically
significant
and
Pearson's
correlation
coefficient were used as tests of significance.
RESULTS
This study included 30 adult patients
with newly diagnosed de novo AML. There is
a highly statistically significant increase in the
age of the patients with CD81 positive
expression compared to those with negative
expression (P=0.003) (Table 1). There was a
statistically significant difference between
385 | P a g e
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both CD81+ and CD81- expression as regards
FAB classification (Table 2).
According to CD81 expression on BM
blast cells, 13 of the AML patients were
CD81+ with mean 31.15  12.14 ranging
from (21 – 66) and 17 of the AML patients
were CD81- with mean 9.06  3.78 ranging
from (3 – 19).There was15 patients (50%) of

the negative CD81 expression achieved
complete remission (CR), 13 patients (43%)
of the positive CD81 expression did not
achieve CR, while 2 patients not evaluated
Regarding survival rates in 28 AML
patients, OS (within 12 months) was 71.4%
(Table 5) and DFS (within 11 months) was
53.6% (Table 6) as shown in (Figure 1).

Table (1): Demographic data of AML patients and studied groups according to CD81
expression
Demographic
AML patients
CD81+
CD81P-value
data
(n= 30)
(n=13)
(n=17)
40.9 ± 15.44
50.00 ± 14.42
33.94 ± 12.53
Age(years)
Mean ± SD
(17 – 75)
Gender
Frequency
%
Frequency
%
Frequency
Male
24
80
12
92.3
12
Female
6
20
1
7.7
5
*Statistically significant difference between CD 81+ & CD 81- ( P< 0.05 )
+Test of significant Fisher`s exact test (not significant)

0.003*
%
70.6
29.4

Table (2): FAB classification in the AML patients according to CD81 expression
FAB Types
AML patients
CD 81+
CD 81(n= 30)
(n=13)
(n=17)
Frequency
%
Frequency
%
Frequency
%
2
6.7
1
7.7
1
5.9
M1

0.2+

P-value
0.02*

M2

10

33.3

2

15.4

8

47.1

M4

12

40

4

30.8

8

47.1

M5b

3

10

3

23.1

0

0

M6

2

6.7

2

15.4

0

0

M7

1

3.3

1

7.7

0

0

*Statistically significant difference between CD 81- & CD 81+ ( P< 0.05 )

Table (3) CD81 expression in the studied group
Number
13
CD 81+
17
CD 81-
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Mean
31.15 ± 12.14
9.06 ± 3.78

Range
21-66%
3-19%
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Table (4) Response to treatment in AML patients
Response to treatment
Number
15
CR
13
Non-CR
2
Missed
CR: complete remission
Table (5): OS in the AML patients.
OS
12 month

Doi10.21608/zumj.2020.43038.1946

AML patients
Frequency
50
43
7

All patients
(n=28)
71.4 %

OS: overall survival
Table (6): DFS in the AML patients.
DFS
11 month
DFS: disease free survival

All patients
(n=28)
53.6 %

Figure (1): Kaplan-Meier curves for overall survival and disease free survival in AML patients,
and studied groups according to CD81 expression
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D
Figure (1):
(a) Kaplan-Meier curve for overall survival (OS) in AML patients ranged from (8-12 months) with median 11.57 (OS
in 28 AML patients was 71.4%). (b) Kaplan-Meier curve for disease free survival (DFS) in AML patients (DFS in 28
AML patients was 53.6%). (c) Kaplan-Meier curve shows that there was a highly statistically significant difference
between both CD81+ and CD81- expression as regards OS (P= 0.00).(d) Kaplan-Meier curve shows that there was
statistically significant difference between both CD81+ and CD81- expression as regards DFS (P= 0.00).

DISCUSSION
AML is a malignant disorder characterized
by abnormal growth and differentiation of
hematopoietic stem cells (HSCs), in which
immature myeloid precursors (myeloblasts)
are accumulated in the bone marrow and
peripheral blood. This expansion of immature
myeloid cells occurs at the expense of the
normal production of their terminally
differentiated counterparts, such as red blood
cells (RBCs), platelets and white blood cells
(WBCs) [9].
CD81 is physiologically implicated in the
re-entry of hematopoietic stem cells into the
quiescent state in order to control self-renewal
after induced proliferation [10]. CD81 is a
glycoprotein that mediates signal transduction
events that is important in multiple processes
as in development of the cell, its activation,
motility and growth. CD81 gene is localized
in the region of tumor suppressor gene and
thus it is a candidate gene for malignancies
[11].Various cellular functions are linked to
CD81 i.e., BCR signaling in B cells [12] B-T
cell interaction and cell entry for different
infectious diseases [13].
CD81+ expression was present in 13/30
(43%) patients of the studied group, and its
level ranged from 21 to 66%, with mean value
31.15±12.14, whereas CD81-expression was
present in 17/30 (57%) patients of the studied
Hussein O., et al
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group, and its level ranged from 3 to 19%,
with mean value of 9.06±3.78. This was in
agreement with Boyer T et al.who stated that
the frequency of positive CD81 expression
was 35% among patients with AML [10].
Overall, eight patients (26.6%) with CD81+
expression died, whereas two patients (6.7%)
with CD81- expression died during induction
therapy, with no statistical difference between
the two expressions. These results could be
explained by the finding of Gonzales F et
al.who proved that blast cells expressing
CD81 were 30 to 50% more resistant to
chemotherapy, and overexpression of CD81
increased AML cell adhesion, migration and
blast homing and engraftment efficiency [14].
As regards response to treatment, 50%
(15/30) of the negative expression patients
shared in this study achieved complete
remission (CR), while 43% (13/30) failed to
respond to treatment. Patients with positive
CD81 expression had a high statistically
significant shorter DFS and shorter OS
compared with patients with negative CD81
expression (P=0.00).
These results were in agreement with those
reported by Boyer T et al. [10] and Gonzales
F et al.[14] who stated that CD81 expression
had a negative effect on patient survival.
CONCLUSION
CD81+ expression has a potential role as a
388 | P a g e
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prognostic marker; its expression is associated
with M4 and M5 FAB subtypes. Moreover,
patients with CD81+ expression have higher
incidence of relapse and decreased OS & DFS
than patients with CD81- expression.
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